An observational study in SLC6A1 Neurodevelopmental Disorder (NDD) and Developmental and Epileptic Encephalopathies (DEE), sponsored by UCB Biopharma SRL. Recruiting at 3 sites in 3 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies in Neurodevelopmental Disorders with a site in United States — 37 open to participants now, 53 under way, 9 of them phase 3. Neurodevelopmental Disorders · United States.
Among the 100 studies in Neurodevelopmental Disorders with a site in United States, this one is the 28th largest by planned enrollment of the 40 observational ones that give a count, is one of 11 that started in 2026, is one of 40 observational ones, reaches primary completion later than 42 of the 52 other live ones, and was the 95th registered.
355 studies on the registry are indexed under Neurodevelopmental Disorders; 144 are open to participants now.
Browse Neurodevelopmental Disorders studies →37 of the 100 studies in Neurodevelopmental Disorders with a site in United States are open now. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 6 mo+
Life University · Sites in United States
Ages 8+
Healing Hope International · Sites in United States
Ages 4–12
GRIN Therapeutics, Inc. · Sites in United States, Australia, Belgium and 10 more countries
Ages 1 mo–18 yrs
Hugo W. Moser Research Institute at Kennedy Krieger, Inc. · Sites in United States
Ages 1 mo–24 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 100 Neurodevelopmental Disorders studies recruiting now, 20 (20%) set no upper age limit and 76 (76%) stop at 75 or younger; 86 take children under 18; 31 take healthy volunteers.
This study: Up to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 13 · Phase 4 1
First in 1996; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 200 across 135 observational studies indexed under Neurodevelopmental Disorders.
Median enrollment 100 across the 60 interventional studies, 158 across the 40 observational. Of the 43 that completed or were terminated, 11 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 100 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 17 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
UCB S.A. has 1 study filed under Neurodevelopmental Disorders — fewer than ten, so there is no comparison to draw.
19 of the studies in Neurodevelopmental Disorders with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT06915480Phase 3Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Reducing Missed Appointments | 2026-12-31 |
| NCT07224581Phase 3GRIN Therapeutics, Inc.Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder | 2027-05 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT03770832Shirley Ryan AbilityLabWearable Sensors and Video Recordings to Monitor Motor Development | 2026-12 |
Add all 19 to your calendar (.ics) → With an account.
Among the 100 studies in Neurodevelopmental Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall objective of this prospective longitudinal natural history study is to collect clinical data to characterize and evaluate the natural course of SLC6A1-NDD and assess the feasibility of certain assessments for the purpose of conducting future clinical studies in patients with this disease.
GTEP01 is a noninterventional, multicenter, multinational, prospective longitudinal natural history study that will be conducted in different countries/languages to prepare for future international clinical studies.
The aim of this study is to characterize the natural course of SLC6A1-NDD through collecting clinical data longitudinally.
Approximately 60 patients with SLC6A1-NDD are planned to be enrolled within 2 age groups, a minimum of approximately 20 patients in each of the 2 age groups. The study consists of Enrollment and Baseline visits followed by 5 study visits over a 2-year Observational Period.
The study population comprises pediatric patients with a diagnosis of SLC6A1-NDD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This age group consists of patients which are \< 6 years at the time of study enrollment.
This age group consists of patients which are between 6 and 17 years at the time of study enrollment.
Seizure frequency by type (countable seizures per 28 days) by visit as compared to Baseline
Time frame: 2 years
Seizure free days per 28 days by visit as compared to Baseline
Time frame: 2 years
Number and proportion of tests completed by visit
Number and proportion of scheduled assessments completed by participants at each study visit for domains relevant to the natural history of SLC6A1 NDD, including epileptic seizures, neurodevelopment, behavioral, communication, sleep, and overall symptom severity.
Time frame: 2 years
Patient retention (dropout by visit and reason for dropout)
Time frame: 2 years
EEG over time: Number/proportion of tests completed by study patients by visit
Time frame: 2 years
Plan to share: Undecided — Not yet confirmed
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for May 2029, 34 months after the start.
Of 70 observational studies under Neurodevelopmental Disorders, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 140. This study's planned 34 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neurodevelopmental Disorders →